Thermo Fisher Scientific PAI1 Monoclonal Antibody (1D5)

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:2,000

View 3 publications 3 publications

Immunohistochemistry (IHC)

-

View 3 publications 3 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:200-1:1,000

-

Flow Cytometry (Flow)

1:200-1:400

-

ELISA (ELISA)

1:10,000

-

Immunoprecipitation (IP)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Human, Mouse

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

1D5

Immunogen

Purified recombinant fragment of human SERPINE1 expressed in E. Coli.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein G

Storage buffer

PBS

Contains

0.05% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2538642

Product Specific Information

MA5-17171 targets SERPINE1 in FACS, IHC, indirect ELISA, and WB applications and shows reactivity with Human samples.

The MA5-17171 immunogen is purified recombinant fragment of human SERPINE1 expressed in E. Coli.

MA5-17171 detects SERPINE1 which has a predicted molecular weight of approximately 45kDa.

Target Information

PAI1 (plasminogen activator inhibitor 1) belongs to serine protease inhibitor superfamily, and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA). Platelets are the main source of the circulating PAI11, but it is synthesized and secreted by many tissue and cell types, including fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells. Expression of PAI11 can be regulated at the transcriptional level by many factors including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and other environmental or physical factors. PAI1 is present at increased levels in various disease states, and has been linked to an increased occurrence of thrombosis in obesity, thrombophilia and the metabolic syndrome. Defects in PAI-1 are characterized by abnormal bleeding. PAI1 mediates inhibition of fibrinolysis by inhibiting the activity of plasminogen activator, and may promote neuronal survival. Other defects in PAI1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency). Alternatively spliced transcript variants encoding different isoforms of PAI1 have been found.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.